Skip to main content

Porcine circovirus type 2 (PCV2) genotyping in Austrian pigs in the years 2002 to 2017



Eight different PCV2 genotypes with varying prevalence and clinical impact have been described so far. PCV2 infection is still widespread among the vaccinated population and several experimental studies have clearly demonstrated that there is no induction of a 100% cross-protective immunity between the PCV2 genotypes. Hence, PCV2a-based vaccines may be ineffective. In this longitudinal study, the PCV2 genotype and haplotype evolution in Austria in the years 2002 to 2017 was investigated by phylogenetic analysis of 462 bp-long sequences of the capsid protein gene (ORF2). The obtained findings may be of practical relevance for the future development of vaccination strategies.


One hundred thirty four of a total of 161 formalin-fixed and paraffin wax-embedded samples could be sequenced successfully. There was no significant influence of storage time on sequencing success or quality. PCV2a (8.2%), PCV2b (77.6%), PCV2d (13.4%), and PCV2g (0.8%) were found. PCV2d was first detected as early as in 2004. PCV2g was described once in 2009. Both global PCV2 genotype shifts were observed. PCV2a occurred with a low prevalence during the first study years only in samples from non-vaccinated swine herds and was gradually replaced by PCV2b until 2011. PCV2b was the most prevalent genotype over the whole study period and was detected in samples from vaccinated and non-vaccinated herds. During the last two study years, the prevalence of PCV2d increased, although at this point almost all herds were vaccinated. The haplotype diversity was high, but the nucleotide diversity was low. Especially for genotype PCV2b, an increase in haplotype diversity could be described during the first study years.


Extensive PCV2a-derived vaccination resulted in a reduction of prevalence and in a stabilization of genotype PCV2a, whereas genotypes PCV2b and PCV2d evolved as a consequence of natural and vaccination-induced selection. An ongoing virus circulation may be the result of reduced vaccine-induced protection.


Since its first description in pigs showing the clinical symptoms of wasting [1, 2], porcine circovirus type 2 (PCV2) has emerged as one of the most destructive viral diseases with high economic impact. Eight PCV2 genotypes, PCV2a through PCV2h, have been described so far [3]. Whereas PCV2a, PCV2b and PCV2d occur worldwide with high prevalence and cause moderate to severe clinical symptoms [4, 5], PCV2c, PCV2e and PCV2f are less prevalent, occur geographically limited and are considered to be non-pathogenic [6,7,8]. The genotypes g and h have been additionally proposed, but only little information is available about them [3]. It is well documented that PCV2 continues to evolve, which is reflected by changes in the prevalence of genotypes [9]. Since the mid-2000s, two global PCV2 genotype shifts have been observed [10]. Around 2003, PCV2a was replaced by PCV2b [10, 11]. Since 2012, the prevalence of PCV2d increased and this genotype may in future replace PCV2b [5, 12, 13].

In Austria, porcine circovirus type 2 systemic disease (PCV2-SD) was reported for the first time in 2002 [14]. Vaccination programs against PCV2 were implemented in 2008 mainly in piglets. A 100% PCV2 prevalence was determined in domestic pigs in Germany [15] and the situation in Austria is for sure comparable, even if this has never been investigated. Two different vaccine types are available: an inactivated recombinant PCV1-chimera expressing PCV2 protein and an inactivated PCV2a-derived vaccine, which are licensed for use in piglets and sows [16]. After the implementation of PCV2 vaccination programs in Austria, the vaccination rate increased continuously from 3.3% in 2008 to 65.9% in 2011 of pigs on farrow-to-finish farms and from 6.2% in 2008 to 97.9% in 2011 of pigs on finishing farms [17]. However, the first reported global genotype shift from PCV2a to PCV2b started before the implementation of vaccination and only the second global genotype shift from PCV2b to PCV2d occurred in the presence of widespread vaccination.

The open reading frame (ORF) 2 encodes the capsid protein and is the primary target for the immune system. This region is under high selection pressure and shows a higher mutation rate than the other parts of the PCV2 genome [5, 18]. Both, natural and vaccination-induced selection are discussed to have an influence on PCV2 evolution [10]. Until today, the prevalence of the different PCV2 genotypes in Austrian swine herds as well as the variability of strains have not been investigated. The present study is the first longitudinal study of PCV2 genotype and haplotype evolution in Austria in the years 2002 to 2017. Additionally, this study offered the opportunity to investigate the influence of long-term storage of formalin-fixed and paraffin wax-embedded tissue on molecular biological-based methods such as Sanger sequencing.


A total of 134 out of 161 (83.2%) samples could be sequenced successfully (NCBI GenBank acc. no. MN150551-MN150684; Additional file 1). The number of complete sequences per year in relation to the number of samples examined is shown in Additional file 2. In the years 2009, 2010, 2011, and 2017, all samples could be sequenced. In the other study years, between one and five samples per year could not be sequenced or did not reveal a complete sequence of 462 bp length. Storage time does not impact successful DNA sequencing (p = 0.106).

Sequences of PCV2a, PCV2b, PCV2d, and PCV2g were found (Fig. 1, Additional file 2). PCV2c, PCV2e, PCV2f, or PCV2h were not obtained in the sample set. The vaccination status of the swine herds is shown in Additional file 1. PCV2a was identified in 11/134 (8.2%) of the cases and was limited to the years 2002 to 2006, 2009, and 2011. Since 2012, this genotype was not detected. 9/11 samples came from non-vaccinated herds, the vaccination status of two herds was unknown. Ten of the sequences formed one clade, only MN150657 occurred in a separate clade. PCV2b showed the highest prevalence of 77.6% (104/134 samples) and was detected in every study year. In 2007, 2008, 2010, and 2013 all samples were of this genotype. Forty-three samples from non-vaccinated and 33 samples from vaccinated herds were submitted. The vaccination status of 28 herds was unknown. The PCV2b sequences formed three clades. Genotype PCV2d was detected in 2004 for the first time. After a 7-years-break, it was found in two samples from 2012 and from 2014 on in every study year. The PCV2d sequences formed one clade. The overall prevalence of this genotype was 13.4% (18/134 samples). Twelve samples came from vaccinated herds and one from a non-vaccinated herd. The vaccination status of four herds was unknown. Genotype PCV2g was represented by only one sequence from the year 2009 (0.8%; 1/134 samples). The vaccination status of this herd was unknown.

Fig. 1

Maximum likelihood tree constructed with 105 capsid protein gene sequences. The tree is constructed from sequences of the present study (acc. no. MN150551-MN150684) and 32 representative PCV2 sequences of different genotypes (PCV2a labeled blue: acc. no. AF201305, AY424401, EU148507, EU386606, FJ483938, KP231099; PCV2b labeled red: acc. no. AY256457, DQ218419, EU545549, HQ591367, JN382175, KY806030, KY806064; PCV2c labeled turquoise: acc. no. EU148503; PCV2d labeled green: acc. no. JN006448, JF683408, JX912915; PCV2e labeled violet: acc. no. KT795288; PCV2f labeled orange: acc. no. HQ591381, KT369067, LC004746, LC004749, LC008134, MG739618; PCV2g labeled pink: acc. no. AY713470, DQ151643, JX948768, KP420197; PCV2h labeled brown: GQ449669, KC514969, KM042403, MH465473). NC_001792 served as outgroup. The tree with the highest log likelihood (− 3808.33) is shown. The percentage of trees in which the associated taxa clustered together is shown next to the branches (1000 replicates, in %)

Additionally to the determination of genotypes, the variants of the nucleotide sequences were evaluated and 72 different haplotypes were detected. The haplotypes were consecutively numbered (HT1-HT72). HT1 to HT12 were identified more frequently, whereas HT13 to HT72 were found only once. The associated accession numbers are listed in Additional file 2. HT1 (PCV2b) was detected in 34 samples and occurred in all study years except of 2014, 2016 and 2017. In 2002 and 2003, only this PCV2b haplotype was identified and HT1 dominated the PCV2b genotype until 2006. In 2014, HT2 (PCV2b) was the predominating haplotype. In eleven samples positive for PCV2a, nine different haplotypes were detected. For PCV2b, 51 haplotypes were identified in 104 samples. In 18 samples positive for PCV2d, eleven haplotypes were found. PCV2g was only represented by one haplotype. Figure 2 shows the development of prevalence and heterogeneity over the years.

Fig. 2

Number of PCV2 sequences and haplotypes per genotype per year. The columns represent the numbers of PCV2 sequences per genotype per year (PCV2a – dark blue, PCV2b – dark red, PCV2d – dark green, PCV2g – pink) and the number of PCV2 haplotypes (HT) per genotype per year (PCV2a – light blue, PCV2b – light red, PCV2d – light green, PCV2g – rose)

The median-joining network showed a radial structure for the PCV2 genotypes a, b and d (Fig. 3a-c). The PCV2a sequences showed the highest haplotype diversity (HD = 0.945), but a low nucleotide diversity (π = 0.017). Only one haplotype was constituted of three samples, all other haplotypes were constituted of one sample. The numbers of mutation steps separating the haplotypes from the main haplotype varied between one and 26. Compared to PCV2a, the median-joining network of PCV2d revealed a lower haplotype (HD = 0.791) and nucleotide (π = 0.003) diversity. Three haplotypes were constituted of two to four samples, all other haplotypes were constituted of one sample. The sequences of HT4 and HT64 as well as HT58 and HT69 differed only by ambiguous nucleotides and therefore formed one haplotype node respectively in the median-joining network. All haplotypes differed by one to two mutations. The PCV2b sequences showed also a high haplotype diversity (HD = 0.883) and a considerably low nucleotide diversity (π = 0.007), which was partly due to the high frequency of one very common haplotype, which was shared by 34 individuals. Most haplotypes were constituted of one sample and connected by short branches with this widespread haplotype. Additionally, two further clades consisting of two and seven haplotypes respectively, which were separated by up to twelve and 23 mutation steps from the main haplotype could be distinguished. Genotype PCV2a was mainly associated to the first study years, whereas PCV2d appeared during the last study years. PCV2b occurred during the complete study period.

Fig. 3

Median-joining networks of PCV2a, PCV2b and PCV2d classified according to the year of detection (see legend). The numbers of mutation steps are indicated in red numbers next to the branches. Branches without numbers represent mutation steps of one. A. PCV2a. Except of one haplotype, which is constituted of three samples, all haplotypes are constituted of one sample. The haplotypes are separated by one to 26 mutation steps from the main haplotype. B. PCV2b. One very common haplotype is shared by 34 individuals. Seven haplotypes are constituted of two to nine samples. Most haplotypes are constituted of one sample separated by one to two mutation steps from the main haplotype. Two further clades can be distinguished and the associated haplotypes are separated by up to twelve and 23 mutation steps, respectively, from the main haplotype. C. PCV2d. Except of three haplotypes, which are constituted of two to four samples, all haplotypes are constituted of one sample. The haplotypes are separated by one to two mutations steps from the main haplotype


In the present longitudinal study, PCV2 sequences from 16 consecutive years were analyzed. One major aim was the investigation of the influence of long-term storage of FFPE tissue on molecular biological-based methods as Sanger sequencing. In the past, the effect of long-term storage of tissue sections on the detection rate has mainly been investigated and, especially for immunohistochemistry, a loss of antigenicity proportional to the age of the tissue sections was documented [19]. In situ hybridization (ISH) techniques are not affected, because only minute changes of tissue microarray slides are induced [20]. Kokkat et al. 2013 [21] extracted DNA, RNA and proteins from FFPE tissue and did not determine any reduction in quality or quantity. However, no further molecular biological methods were applied and, up to date, no information about the stability of FFPE material itself is available. In the present study, storage time had no negative influence on success and quality of sequencing. This may be of importance for retrospective studies on different infectious agents in FFPE tissue.

The obtained PCV2 sequences could be assigned to the genotypes a, b, d, and g. PCV2a was the dominant genotype in pig herds from 1996 to the early 2000s [13]. Around 2003, PCV2 was subjected to the first drastic global genotype shift from PCV2a to PCV2b, the latter being the most-prevalent genotype during the following years [5, 11, 22]. In 2002, PCV2-SD was reported in Austrian pigs for the first time [14]. Already by that time, the PCV2a prevalence was low and this genotype was detected only occasionally until 2011. From 2003 on, PCV2b was dominating and PCV2a was completely replaced by PCV2b over time. Also the second global genotype shift from PCV2b to PCV2d [10] became obvious in the Austrian samples characterized by the emergence and spread of PCV2d especially during the last two study years 2016 and 2017. PCV2g was detected for the first time in Austrian pigs in a sample from 2009. This genotype seems to occur with a higher prevalence in wild boars than in domestic pigs and has been described in Asia, Europe and North America [3]. Its impact is still unclear.

Vaccines derived from the PCV2a genotype or its capsid protein have been used worldwide since the mid 2000s and were implemented in Austria in 2008. These vaccines are acknowledged as highly successful in decreasing the disease burden found prior to the introduction of the vaccine and are, therefore, used extensively. Nevertheless, PCV2 infection is still widespread among the vaccinated population and several experimental studies have clearly demonstrated that there is no induction of a 100% cross-protective immunity between the PCV2 genotypes. Pigs vaccinated against one genotype and challenged with another displayed only a decrease in viral load, but were still shedding the virus [9, 23,24,25,26,27,28]. After the implementation of vaccination programs against PCV2 in the year 2008 in Austria, the number of non-vaccinated herds was generally low [17]. In the present study, only single swine herds remained non-vaccinated since 2010 and, PCV2b and PCV2d were detected in both vaccinated and non-vaccinated herds. Especially PCV2d, which is associated with severe clinical symptoms, higher virulence and faster transmission within the pig population, may evade vaccine-induced immunity [29, 30]. It is generally accepted that new genotypes that have not previously circulated may replicate more effectively [26]. Additionally, the reduced vaccine-induced protection against new genotypes facilitates their rise.

In this study, PCV2d was detected in one sample from the year 2004. This genotype was initially identified in 1999 in samples collected in Switzerland [5]. The most recent common ancestor of PCV2d could even be dated back to the 1950s [10]. Genotypes with a presently high economic impact may have circulated within the pig population unrecognized for a long time, which may confer evolutionary advantage.

The PCV2 sequences showed a high haplotype, but a low nucleotide diversity. PCV2 is recognized for its extraordinary high evolutionary rate [5, 9, 31, 32]. The ORF2 encoded capsid protein is the primary target for the immune system and has an even higher evolutionary rate compared to the rest of the PCV2 genome [5]. In the present longitudinal study, samples of 16 consecutive years were investigated and the genotype evolution, but also changes in the heterogeneity especially of the PCV2b genotype are clearly demonstrated. During the first study years, the PCV2b prevalence increased, but the haplotype diversity was low. Since 2007, the haplotype diversity increased. During the last study years, PCV2b was replaced by PCV2d. In the year 2016, the PCV2d sequences showed a high heterogeneity, which decreased in 2017. However, a definite interpretation of the evolution of the PCV2d haplotype diversity is not possible based on these limited data. Due to the permanent and extensive use of vaccination the numbers of viremic pigs as well as the viremia levels themselves were reduced dramatically [33]. Despite continued vaccination, virus loads increased again after several years and the authors concluded that there was evidence for a selectional impact of vaccination on the PCV2 genome mutation [34]. The PCV2a-derived vaccines are not 100% cross-protective in cases of infection with other genotypes and pigs are permanently exposed especially to new genotypes [9]. Also in the present study, the number of vaccinated herds rose rapidly. As a consequence, natural and vaccine-induced selection combined with the permanent circulation of the virus may have facilitated the haplotype evolution, but also the generation of new genotypes. None of the genotypes or haplotypes was associated with a specific geographic origin. Even so, the pig trade may play a significant role in genotype or haplotype distribution, but may also contribute to their evolution [35].


In this longitudinal phylogenetic study, the genetic evolution of PCV2 in Austrian pigs was described over a period of 16 years. PCV2a, PCV2b, PCV2d, and PCV2g were detected, with genotype PCV2b showing the highest overall prevalence. PCV2c, PCV2e, PCV2f, and PCV2h were not obtained in the sample set. PCV2d was first detected in 2004. PCV2g was found once in 2009. Both global PCV2 genotype shifts occurred. Due to vaccination, PCV2a was stabilized and replaced, whereas PCV2b and PCV2d evolved as a consequence of natural and vaccination-induced selection. While the haplotype diversity was high, the nucleotide diversity was low in all investigated genotypes.


A total of 161 formalin-fixed and paraffin-embedded (FFPE) tissue samples from pigs with a history of porcine circovirus type 2 systemic disease (PCV2-SD) or porcine dermatitis and nephropathy syndrome (PDNS) were randomly selected from samples which had been submitted in the years 2002 to 2017 for routine histological examination and PCV2 detection by in situ hybridization (ISH). The samples consisted of lymph nodes (n = 158), kidneys (n = 2) and intestine (n = 1) and they originated from 160 different farms from the Austrian Federal States Upper Austria (n = 73), Lower Austria (n = 17), Styria (n = 16), Burgenland (n = 3), Vienna (n = 3), and Carinthia (n = 1). In 47 cases, the origin of the samples was unknown.

Statistical analysis of the impact of age on successful sequencing

The probability of successful sequencing in the individual study years was tested by binary logistic regression (logit link function). The sequencing results were used as binary results with 0 = not successfully sequenced and 1 = successfully sequenced. The study years were defined as the continuous covariate (IBM® SPSS® Statistics Version 24, IBM Corporation, Armonk, NY, USA). The individual result was the statistical unit and the significance level was set at 5%.

PCR for the detection of PCV2

Ten FFPE tissue sections at 10 μm slice thickness were placed in a 1.5 ml tube, overlaid with 1 ml xylene (Merck, Darmstadt, Germany) and vortexed. The mixture was incubated 5 min at room temperature and centrifuged 5 min at 10.000×g. The supernatant was discarded and the procedure was repeated. After deparaffinization, the pellet was vortexed with 1 ml 100% ethanol (Merck, Darmstadt, Germany) and centrifuged 5 min at 10.000×g. The supernatant was discarded and the washing step with ethanol was repeated. After centrifugation, the ethanol was removed thoroughly with a pipette. The pellet was dried under vacuum in a desiccator (at least 30 min) and stored at 6 °C for a maximum of 1 day until DNA extraction. DNA was extracted using the QIAmp DNA Micro kit (Qiagen, Vienna, Austria) according to the manufacturer’s instructions and stored at − 20 °C. To obtain a sequence of 462 bp of the capsid protein gene, two overlapping PCRs were established and the sequences were assembled. Two primer pairs with the potential to detect all representatives of PCV2 were designed using the Sci Ed Central software package (Scientific Educational Software, Cary, NC, USA) after extensive homology studies on available GenBank sequences of the capsid protein gene. The sequences were submitted to BLAST to search against GenBank sequences and to exclude unintentional cross-reactivity with other organisms. Two hundred and fifty PCV2 sequences showed a 100% homology. Sequences belonging to other pathogens did not match. The PCR reaction master mixture consisted of 12.5 μL Kapa 2G Fast HotStart Ready Mix (Sigma Aldrich, Vienna, Austria), 0.4 μM of each primer (PCR 1 Fw: 5′-ACA TGG TTA CAC GGA TAT TG-3′, PCR 1 Rv: 5′-GRT TAA GGT TGA ATT CTG GC-3′, amplicon length 353 bp; genomic position related to PCV2 sequence acc. no. AY484412: nt 1084–1436; PCR 2 Fw: 5′- TGG CGG GMS GAG TAG TTT A -3′, PCR 2 Rv: 5′- CGC ACC TTC GGA TAT ACT GT − 3′, amplicon length 293 bp; genomic position related to PCV2 sequence acc. no. AY484412: nt 1293–1585), 1 μl MgCl2, 2 μL template DNA and distilled water to a total volume of 25 μL per reaction. The cycler program started with a first heat denaturation step at 94 °C for 2 min, followed by 40 cycles at 94 °C for 30 s, 55 °C for 30 s and 72 °C for 1 min as well as a final extension step at 72 °C for 1 min. An aliquot of 10 μL of each PCR product was analyzed by gel electrophoresis using a 2% Tris acetate-EDTA-agarose gel (Sigma Aldrich, Vienna, Austria). Subsequently, the agarose gel was stained with GelRed® Nucleic Acid Gel Stain (VWR, Vienna, Austria) and bands were visualized using the GEL DOC™ XR+ gel documentation system (BioRad, Vienna, Austria). PCR products showing the expected product sizes of 353 bp in PCR 1 and 293 bp in PCR 2 were evaluated positively.

Sequence analysis

PCR products were extracted using the MinElute PCR Purification kit (Qiagen, Vienna, Austria) and were submitted for Sanger DNA sequencing (Microsynth, Vienna, Austria). Sequences from PCR 1 and PCR 2 were assembled using the software BioEdit Sequence Alignment Editor [36]. Evolutionary analyses were conducted in MEGA X ( [37]. Different haplotypes were identified by the software DAMBE 6.4.51 [38].

The evolutionary history was inferred by using the Maximum Likelihood method and Hasegawa-Kishino-Yano model [39]. Initial trees for the heuristic search were obtained automatically by applying Neighbor-Joining and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. A discrete Gamma distribution was used to model evolutionary rate differences among sites (5 categories (+G, parameter = 0.3525)). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. This analysis involved 105 nucleotide sequences. All positions with less than 95% site coverage were eliminated, i.e., fewer than 5% alignment gaps, missing data, and ambiguous bases were allowed at any position (partial deletion option). There were a total of 462 positions in the final dataset. Thirty-two already published PCV2 sequences were used as reference for the various genotypes [3]. PCV1 was chosen as outgroup. The respective accession numbers (acc. no.) are summarized in Additional file 3. Median-joining haplotype networks [40] were produced with the software Network 5 ( The haplotypes were classified according to the year of detection. Calculations of haplotype diversity (HD) and nucleotide diversity (π) of the PCV2a, PCV2b and PCV2d datasets were conducted in DnaSP v5 ( [41].

Availability of data and materials

The datasets generated and/or analysed during the current study are available in the Mendeley repository (Weissenbacher-Lang, Christiane (2020), "Porcine circovirus type 2 (PCV2) genotyping in Austrian pigs in the years 2002 to 2017", Mendeley Data, v1 ) and in NCBI GenBank (acc. no. MN150551-MN150684).


acc. no.:

Accession number




Deoxyribonucleic acid


Ethylenediaminetetraacetic acid


Formalin-fixed and paraffin-embedded






Haplotype diversity


In situ hybridization


Maximum Composite Likelihood




Open reading frame


Polymerase chain reaction


Porcine circovirus type 1


Porcine circovirus type 2


Porcine circovirus type 2 systemic disease


Porcine dermatitis and nephropathy syndrome



sample ID:

Sample identity


Nucleotide diversity


  1. 1.

    Allan GM, McNeilly F, Kennedy S, Daft B, Clark EG, Ellis JA, et al. Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe. J Vet Diagn Investig. 1998;10(1):3–10.

    CAS  Article  Google Scholar 

  2. 2.

    Ellis JA, Hassard LE, Clark EG, Harding JC, Allan GM, Willson P, et al. Isolation of circovirus from lesions of pigs with postweaning multisystemic wasting syndrome. Can Vet J. 1998;39(1):44.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Franzo G, Segalés J. Porcine circovirus 2 (PCV-2) genotype update and proposal of a new genotyping methodology. PLoS One. 2018;13(12):e0208585.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Guo L, Fu Y, Wang Y, Lu Y, Wei Y, Tang Q, et al. A porcine circovirus type 2 (PCV2) mutant with 234 amino acids in capsid protein showed more virulence in vivo, compared with classical PCV2a/b strain. PLoS One. 2012;7(7):e41463.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Xiao CT, Halbur PG, Opriessnig T. Global molecular genetic analysis of porcine circovirus type 2 (PCV2) sequences confirms the presence of four main PCV2 genotypes and reveals a rapid increase of PCV2d. J Gen Virol. 2015;96(7):1830–41.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Dupont K, Nielsen EO, Bækbo P, Larsen LE. Genomic analysis of PCV2 isolates from Danish archives and a current PMWS case-control study supports a shift in genotypes with time. Vet Microbiol. 2008;128(1–2):56–64.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Wang F, Guo X, Ge X, Wang Z, Chen Y, Cha Z, et al. Genetic variation analysis of Chinese strains of porcine circovirus type 2. Virus Res. 2009;145(1):151–6.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Bao F, Mi S, Luo Q, Guo H, Tu C, Zhu G, et al. Retrospective study of porcine circovirus type 2 infection reveals a novel genotype PCV2f. Transbound Emerg Dis. 2018;65(2):432–40.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Karuppannan AK, Opriessnig T. Porcine circovirus type 2 (PCV2) vaccines in the context of current molecular epidemiology. Viruses. 2017;9(5):1–15.

    Article  CAS  Google Scholar 

  10. 10.

    Franzo G, Cortey M, Segalés J, Hughes J, Drigo M. Phylodynamic analysis of porcine circovirus type 2 reveals global waves of emerging genotypes and the circulation of recombinant forms. Mol Phylogenet Evol. 2016;100:269–80.

    PubMed  Article  Google Scholar 

  11. 11.

    Patterson AR, Opriessnig T. Epidemiology and horizontal transmission of porcine circovirus type 2 (PCV2). Anim Health Res Rev. 2010;11(2):217–34.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Franzo G, Cortey M, Segalés J, Hughes J, Drigo M. Phylodynamic analysis of porcine circovirus type 2: methodological approach and datasets. Data Br. 2016;8:549–52.

    Article  Google Scholar 

  13. 13.

    Kwon T, Lee DU, Yoo SJ, Je SH, Shin JY, Lyoo YS. Genotypic diversity of porcine circovirus type 2 (PCV2) and genotype shift to PCV2d in Korean pig population. Virus Res. 2017;228:24–9.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Schmoll F, Opriessnig T, Schilcher F, Leeb B, Bauder B, Schuh M. Erstmalige Beschreibung des Postweaning multisystemic wasting syndrome (PMWS) in einem österreichischen Schweinebetrieb. Wien Tierarztl Monatsschr. 2002;89(2):50–6.

    CAS  Google Scholar 

  15. 15.

    Reiner G, Bronnert B, Hohloch C, Fresen C, Haack I, Willems H, et al. Qualitative and quantitative distribution of PCV2 in wild boars and domestic pigs in Germany. Vet Microbiol. 2010;145(1–2):1–8.

    PubMed  Article  Google Scholar 

  16. 16.

    Segalés J. Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Rev Vaccines. 2015;14(3):473–87.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Raith J, Trauffler M, Firth CL, Lebl K, Schleicher C, Köfer J. Influence of porcine circovirus type 2 vaccination on the level of antimicrobial consumption on 65 Austrian pig farms. Vet Rec. 2016;178(20):504.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Segalés J, Olvera A, Grau-Roma L, Charreyre C, Nauwynck HJ, Larsen LE, et al. PCV-2 genotype definition and nomenclature. Vet Rec. 2008;162(26):867–8.

    PubMed  Article  Google Scholar 

  19. 19.

    Grillo F, Pigozzi S, Ceriolo P, Calamaro P, Fiocca R, Mastracci L. Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem Cell Biol. 2015;144(1):93–9.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Karlsson C, Karlsson MG. Effects of long-term storage on the detection of proteins, DNA, and mRNA in tissue microarray slides. J Histochem Cytochem. 2011;59(12):1113–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Kokkat TJ, Patel MS, McGarvey D, LiVolsi VA, Baloch ZW. Archived formalin-fixed paraffin-embedded (FFPE) blocks: a valuable underexploited resource for extraction of DNA, RNA, and protein. Biopreserv Biobank. 2013;11(2):101–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Beach NM, Meng XJ. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res. 2012;164(1–2):33–42.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Beach NM, Ramamoorthy S, Opriessnig T, Wu SQ, Meng XJ. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtype. Vaccine. 2010;29(2):221–32.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Li J, Yu T, Zhang F, Wang X, Zhou J, Gao X, et al. Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233. Arch Virol. 2017;162(1):235–46.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Opriessnig T, Xiao CT, Halbur PG, Gerber PF, Matzinger SR, Meng XJ. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions. Vaccine. 2017;35(2):248–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Opriessnig T, O’Neill K, Gerber PF, de Castro AMMG, Gimenez-Lirola LG, Beach NM, et al. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection. Vaccine. 2013;31(3):487–94.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Opriessnig T, Gerber PF, Xiao CT, Mogler M, Halbur PG. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 US variant mPCV2b strain. Vaccine. 2014;32(2):230–7.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Rose N, Andraud M, Bigault L, Jestin A, Grasland B. A commercial PCV2a-based vaccine significantly reduces PCV2b transmission in experimental conditions. Vaccine. 2016;34(33):3738–45.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Seo HW, Park C, Kang I, Choi K, Jeong J, Park SJ, et al. Genetic and antigenic characterization of a newly emerging porcine circovirus type 2b mutant first isolated in cases of vaccine failure in Korea. Arch Virol. 2014;159(11):3107–11.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Xiao CT, Halbur PG, Opriessnig T. Complete genome sequence of a novel porcine circovirus type 2b variant present in cases of vaccine failures in the United States. J Virol. 2012;86(22):12469.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Firth C, Charleston MA, Duffy S, Shapiro B, Holmes EC. Insights into the evolutionary history of an emerging livestock pathogen: porcine circovirus 2. J Virol. 2009;83(24):12813–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Franzo G, Tucciarone CM, Cecchinato M, Drigo M. Porcine circovirus type 2 (PCV2) evolution before and after the vaccination introduction: a large scale epidemiological study. Sci Rep. 2016;6:39458.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Dvorak CMT, Yang Y, Haley C, Sharma N, Murtaugh MP. National reduction in porcine circovirus type 2 prevalence following introduction of vaccination. Vet Microbiol. 2016;189:86–90.

    PubMed  Article  Google Scholar 

  34. 34.

    Reiner G, Hofmeister R, Willems H. Genetic variability of porcine circovirus 2 (PCV2) field isolates from vaccinated and non-vaccinated pig herds in Germany. Vet Microbiol. 2015;180(1–2):41–8.

    PubMed  Article  Google Scholar 

  35. 35.

    Drew TW. The emergence and evolution of swine viral diseases: to what extent have husbandry systems and global trade contributed to their distribution and diversity? Rev Sci Tech. 2011;30(1):95.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT, Nucleic acids symposium series. London: Information Retrieval Ltd., c1979-c2000; 1999. p. 95–8.

    Google Scholar 

  37. 37.

    Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35(6):1547–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Xia X. DAMBE5: a comprehensive software package for data analysis in molecular biology and evolution. Mol Biol Evol. 2013;30(7):1720–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Hasegawa M, Kishino H, Yano T. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J Mol Evol. 1985;22(2):160–74.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Bandelt H-J, Forster P, Röhl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol. 1999;16(1):37–48.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009;25(11):1451–2.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


Not applicable.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information




CWL, RB, LS and HW contributed to conception and design of the study and defined the investigated sample set. TK and VM were mainly responsible for the lab part and the acquisition of data (DNA extraction, PCR, Sanger sequencing). CWL carried out the phylogenetic and statistical analyses. All authors contributed to the interpretation of data. CWL drafted the manuscript. All authors critically revised it and gave their final approval.

Corresponding author

Correspondence to Christiane Weissenbacher-Lang.

Ethics declarations

Ethics approval and consent to participate

As the samples were collected during routinely carried out sections and were subsequently archived, no ethics committee approval was necessary. Compliance with federal law (Tierversuchsgesetz (Austrian federal law for animal experiments); 2012. https://www.ris.bka. = Bundesnormen&Gesetzesnummer = 20008142) and good scientific practice (Good Scientific Practice of the University for Veterinary Medicine Vienna; 2013. is ensured. The owners’ consents for participation and consecutive publication of gained data were signed by the animal owners before admission of the pigs. No further administrative permissions were required to use the samples.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

The table contains accession numbers of the sequences included in the present study, internal sample ID (PCV2 genotype_haplotype_ serial number_study year_ origin_Austrian Federal State), tissue used for DNA extraction, and vaccination status of the herd.

Additional file 2.

The table contains the PCV2 haplotypes per year subdivided by the genotypes PCV2a, b, d, and g, the number of complete sequences relating to the number of investigated samples, the frequency of occurrence of this haplotype in the respective year and the associated accession numbers.

Additional file 3.

The table contains accession numbers, origin, genotype, and species of the sequences used as reference strains and outgroup for the phylogenetic tree.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weissenbacher-Lang, C., Kristen, T., Mendel, V. et al. Porcine circovirus type 2 (PCV2) genotyping in Austrian pigs in the years 2002 to 2017. BMC Vet Res 16, 198 (2020).

Download citation


  • Porcine circovirus type 2
  • Genotypes
  • Haplotypes
  • Genotype shift